Vaccination Plus Ontak in Patients With Metastatic Melanoma

• Status: Terminated
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Collaborator: Eisai Inc.
• Treatments: Denileukin diftitox; Vaccines

Criteria

Inclusion Criteria:

• Melanoma with evidence of metastatic disease

• Life expectancy of at least 12 weeks.

• Karnofsky performance status index of greater than or equal to 80%.

• Adequate hematopoietic, renal, and hepatic function, defined as:

• Patient must express HLA-A2

• Tumor biopsy: patient must agree to undergo biopsy of accessible tumor before and after therapy, when feasible, to study tumor cell properties and characteristics of immune cells.

• EKG without evidence of arrhythmia or changes that indicate acute ischemia.

• Pulse oximetry showing oxygen saturation of at least 90% on room air.

Exclusion Criteria:

• Significant cardiovascular disease, or cardiac arrhythmia requiring medical intervention.

• Pregnant or nursing women.

• Biological therapy in the 4 weeks prior to the start of dosing.

• Patients with intrinsic immunosuppression, including seropositivity for HIV antibody.

• Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis C.

• Concurrent systemic corticosteroids (except physiologic replacement doses)or other immunosuppressive drugs (eg. cyclosporin A).

• Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent.

• Active or history of autoimmune disease

• Active gastrointestinal bleeding or uncontrolled peptic ulcer disease.

• Presence of untreated brain metastases.